Skip to main content
See every side of every news story
Published • loading... • Updated

Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms

Summary by The Manila Times
ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®Eton has licensed patent rights from Baylor College of Medicine covering the...

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Manila Times broke the news in Manila, Philippines (the) on Monday, November 2, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal